🎉 M&A multiples are live!
Check it out!
| Company | Headquarters | Sector | Stock Price | Enterprise Value | EV/Revenue | EV/EBITDA |
|---|---|---|---|---|---|---|
| AstraZeneca | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £141 | $318B | 5.4x | 15.6x |
| GSK | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics, Vaccines & Immunotherapies | £18 | $118B | 2.7x | 8.0x |
| Haleon | United Kingdom of Great Britain and Northern Ireland | Health & Beauty, Drug Development & Therapeutics | £4 | $54.1B | 3.6x | 14.5x |
| Hikma Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £16 | $6.0B | 1.8x | 7.1x |
| Genus | United Kingdom of Great Britain and Northern Ireland | Agriculture, Genomics & Personalized Medicine, Bioindustrials | £28 | $2.8B | 3.1x | 16.9x |
| Oxford Nanopore Techs | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics, Medical Devices | £2 | $1.6B | 5.5x | -13.0x |
| Oxford BioMedica | United Kingdom of Great Britain and Northern Ireland | Contract Research & Manufacturing, Drug Development & Therapeutics | £9 | $1.5B | 6.9x | 687.0x |
| HUTCHMED | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £2 | $1.5B | 2.6x | -64.1x |
| Allergy Therapuetics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $1.1B | 12.8x | -32.3x |
| International Biotechnology Trust | United Kingdom of Great Britain and Northern Ireland | Private Equity, Asset Management | £10 | $456M | N/A | N/A |
| Avacta Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Pharma Diagnostics & Analytics | £1 | $331M | 153.3x | -10.4x |
| Faron Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £2 | $276M | N/A | -10.0x |
| Animalcare Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £3 | $252M | 2.1x | 10.6x |
| Shield Therapeutics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $192M | 3.6x | -21.2x |
| Scancell | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $163M | 57.3x | -8.6x |
| PureTech Health | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Biopharmaceuticals | £1 | $140M | N/A | -1.0x |
| Bioventix | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics | £18 | $120M | 6.9x | 9.1x |
| 4basebio | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Genomics & Personalized Medicine | £6 | $96.9M | 40.0x | -4.3x |
| Eco Animal Health Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £1 | $82.8M | 0.7x | 8.1x |
| Provexis | United Kingdom of Great Britain and Northern Ireland | Nutraceuticals & Cosmeceuticals | £0 | $30.9M | N/A | N/A |
| Eden Research | United Kingdom of Great Britain and Northern Ireland | Agriculture, Bioindustrials | £0 | $25.6M | 3.8x | -9.5x |
| Futura Medical | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $5.3M | N/A | N/A |
| GenIP | United Kingdom of Great Britain and Northern Ireland | Vertical AI Applications, Pharma Diagnostics & Analytics | £0 | $2.1M | N/A | N/A |
Valuation multiples as of last 12 months (LTM). Stock prices as of January 18, 2026. Financial data powered by Morningstar and FactSet.
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.